Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. more
Time Frame | AVXL | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.93% | -2.27% | -0.57% |
1-Month Return | -4.84% | -3.96% | 1.21% |
3-Month Return | 59.32% | -9.7% | 7.57% |
6-Month Return | 126.81% | -3.37% | 11.45% |
1-Year Return | 0.12% | 3.71% | 28.48% |
3-Year Return | -54.42% | 3.8% | 29.52% |
5-Year Return | 246.72% | 39.78% | 90.66% |
10-Year Return | 1162.69% | 106.91% | 203.75% |
Sep '19 | Sep '20 | Sep '21 | Sep '22 | Sep '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Cost of Revenue | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Gross Profit | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Operating Expenses | 28.81M | 30.94M | 41.95M | 50.99M | 55.76M | [{"date":"2019-09-30","value":51.67,"profit":true},{"date":"2020-09-30","value":55.49,"profit":true},{"date":"2021-09-30","value":75.23,"profit":true},{"date":"2022-09-30","value":91.44,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Operating Income | (28.75M) | (30.76M) | (41.92M) | (54.40M) | (47.50M) | [{"date":"2019-09-30","value":-2875185800,"profit":false},{"date":"2020-09-30","value":-3075837100,"profit":false},{"date":"2021-09-30","value":-4192082400,"profit":false},{"date":"2022-09-30","value":-5439558000,"profit":false},{"date":"2023-09-30","value":-4749800000,"profit":false}] |
Total Non-Operating Income/Expense | 2.60M | 5.01M | 4.39M | 4.31M | 8.23M | [{"date":"2019-09-30","value":31.52,"profit":true},{"date":"2020-09-30","value":60.86,"profit":true},{"date":"2021-09-30","value":53.29,"profit":true},{"date":"2022-09-30","value":52.39,"profit":true},{"date":"2023-09-30","value":100,"profit":true}] |
Pre-Tax Income | (26.21M) | (26.26M) | (37.64M) | (47.62M) | (47.50M) | [{"date":"2019-09-30","value":-2621279800,"profit":false},{"date":"2020-09-30","value":-2625780600,"profit":false},{"date":"2021-09-30","value":-3764106900,"profit":false},{"date":"2022-09-30","value":-4761942700,"profit":false},{"date":"2023-09-30","value":-4749800000,"profit":false}] |
Income Taxes | 82.18K | 22.66K | 267.56K | 358.49K | (7.00K) | [{"date":"2019-09-30","value":22.92,"profit":true},{"date":"2020-09-30","value":6.32,"profit":true},{"date":"2021-09-30","value":74.64,"profit":true},{"date":"2022-09-30","value":100,"profit":true},{"date":"2023-09-30","value":-1.95,"profit":false}] |
Income After Taxes | (26.29M) | (26.28M) | (37.91M) | (47.98M) | (47.49M) | [{"date":"2019-09-30","value":-2629497900,"profit":false},{"date":"2020-09-30","value":-2628047000,"profit":false},{"date":"2021-09-30","value":-3790863400,"profit":false},{"date":"2022-09-30","value":-4797791900,"profit":false},{"date":"2023-09-30","value":-4749100000,"profit":false}] |
Income From Continuous Operations | (26.29M) | (26.28M) | (37.91M) | (47.98M) | (47.51M) | [{"date":"2019-09-30","value":-2629497900,"profit":false},{"date":"2020-09-30","value":-2628047000,"profit":false},{"date":"2021-09-30","value":-3790863400,"profit":false},{"date":"2022-09-30","value":-4797791900,"profit":false},{"date":"2023-09-30","value":-4750500000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-09-30","value":"-","profit":true},{"date":"2020-09-30","value":"-","profit":true},{"date":"2021-09-30","value":"-","profit":true},{"date":"2022-09-30","value":"-","profit":true},{"date":"2023-09-30","value":"-","profit":true}] |
Net Income | (26.29M) | (26.28M) | (37.91M) | (47.98M) | (47.49M) | [{"date":"2019-09-30","value":-2629497900,"profit":false},{"date":"2020-09-30","value":-2628047000,"profit":false},{"date":"2021-09-30","value":-3790863400,"profit":false},{"date":"2022-09-30","value":-4797791900,"profit":false},{"date":"2023-09-30","value":-4749100000,"profit":false}] |
EPS (Diluted) | (0.54) | (0.45) | (0.53) | (0.62) | (0.60) | [{"date":"2019-09-30","value":-54,"profit":false},{"date":"2020-09-30","value":-45,"profit":false},{"date":"2021-09-30","value":-53,"profit":false},{"date":"2022-09-30","value":-62,"profit":false},{"date":"2023-09-30","value":-60,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
AVXL | |
---|---|
Cash Ratio | 11.81 |
Current Ratio | 12.04 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
AVXL | |
---|---|
ROA (LTM) | -20.43% |
ROE (LTM) | -30.03% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
AVXL | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
AVXL | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 5.42 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
PEG | NM |
Anavex Life Sciences Corp (AVXL) share price today is $8.46
Yes, Indians can buy shares of Anavex Life Sciences Corp (AVXL) on Vested. To buy Anavex Life Sciences Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AVXL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Anavex Life Sciences Corp (AVXL) via the Vested app. You can start investing in Anavex Life Sciences Corp (AVXL) with a minimum investment of $1.
You can invest in shares of Anavex Life Sciences Corp (AVXL) via Vested in three simple steps:
The 52-week high price of Anavex Life Sciences Corp (AVXL) is $10.45. The 52-week low price of Anavex Life Sciences Corp (AVXL) is $3.25.
The price-to-earnings (P/E) ratio of Anavex Life Sciences Corp (AVXL) is
The price-to-book (P/B) ratio of Anavex Life Sciences Corp (AVXL) is 5.42
The dividend yield of Anavex Life Sciences Corp (AVXL) is 0.00%
The market capitalization of Anavex Life Sciences Corp (AVXL) is $703.80M
The stock symbol (or ticker) of Anavex Life Sciences Corp is AVXL